Pharmaceutical company Grünenthal has announced the acquisition of US-based Valinor Pharma, LLC and its product Movantik® (naloxegol), with a total deal value of approximately $250 million, inclusive of all royalty obligations. The acquisition further strengthens Grünenthal’s presence in the United States and adds to its growing portfolio of established medicines. Movantik® is an oral treatment…
